A toll-like receptor 3 ligand enhances protective effects of vaccination against Marek's disease virus and hinders tumor development in chickens

Viral Immunology

Volumn 25, Issue 5, 2012, Pages 394-401

  Parvizi, Payvand ^a   Mallick, Amirul Islam ^a   Haq, Kamran ^a,b   Haghighi, Hamid R ^a   Orouji, Shahriar ^a   Thanthrige Don, Niroshan ^a   St Paul, Michael ^a   Brisbin, Jennifer T ^a   Read, Leah R ^a   Behboudi, Shahriar ^c   Sharif, Shayan ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE; HERPESVIRUS OF TURKEY VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CHICKEN; CONTROLLED STUDY; DRUG POTENTIATION; MARDIVIRUS; MAREK DISEASE; NONHUMAN; SPLEEN; VACCINATION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; CHICKENS; HERPESVIRUS 1, MELEAGRID; HERPESVIRUS 3, GALLID; INTERFERON-GAMMA; INTERLEUKIN-10; MAREK DISEASE; MAREK DISEASE VACCINES; POLY I-C; TOLL-LIKE RECEPTOR 3; VACCINATION; VIRAL LOAD;

GALLID HERPESVIRUS 2; GALLUS GALLUS; MELEAGRID HERPESVIRUS 1;

EID: 84867201857     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0033     Document Type: Article

References (47)

1. Abdul-Careem MF, Hunter BD, Nagy E, et al.: Development of a real-time PCR assay using SYBR Green chemistry for monitoring Marek's disease virus genome load in feather tips. J Virol Methods 2006;133:34-40.
2. Abdul-Careem MF, Hunter BD, Parvizi P, Haghighi HR, Thanthrige-Don N, and Sharif S: Cytokine gene expression patterns associated with immunization against Marek's disease in chickens. Vaccine 2007;25:424-432.
3. Abdul-Careem MF, Hunter BD, Sarson AJ, et al.: Host responses are induced in feathers of chickens infected with Marek's disease virus. Virology 2008;20;370:323-332.
4. Abdul-Careem MF, Hunter DB, Shanmuganathan S, Haghighi HR, Read L, Heidari M, and Sharif S: Cellular and cytokine responses in feathers of chickens vaccinated against Marek's disease. Vet Immunol Immunopathol 2008;126: 362-366.
5. Abdul-Careem MF, Javaheri-Vayeghan A, Shanmuganathan S, et al.: Establishment of an aerosol-based Marek's disease virus infection model. Avian Dis 2009;53:387-391.
6. Baigent SJ: Marek's disease virus: biology and life cycle. In: Marek's Disease: An Evolving Problem, 1st ed. (Nair V. and Davison F, eds.). Elsevier, Great Britain, 2004.
7. Baigent SJ, Smith LP, Nair VK, and Currie RJ: Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection. Vet Immunol Immunopathol 2006;112: 78-86.
8. Beck B,DorfelD, Lichtenegger FS, et al.: Effects of TLR agonists on maturation and function of 3-day dendritic cells fromAML patients in complete remission. J Transl Med 2011;9:151.
9. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, and Ahmed R: Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003;9:540-547.
10. Boyd A, Philbin VJ, and Smith AL: Conserved and distinct aspects of the avian Toll-like receptor (TLR) system: implications for transmission and control of bird-borne zoonoses. Biochem Soc Trans 2007;35:1504-1507.
11. Bublot M, and Sharma J: Vaccination against Marek's disease. In: Marek's Disease: An Evolving Problem, 1st ed. (Nair V. and Davison F, eds.). Elsevier, Great Britain, 2004.
12. Buza JJ, and Burgess SC: Modeling the proteome of a Marek's disease transformed cell line: a natural animal model for CD30 overexpressing lymphomas. Proteomics 2007;7:1316-1326.
13. Calnek BW: Pathogenesis of Marek's disease virus infection. In: Marek's Disease. (Hirai K, ed.). Springer-Verlag, Berlin, 2001, pp. 25-55.
14. Calnek BW: Marek's disease-a model for herpesvirus oncology. Crit Rev Microbiol 1986;12:293-320.
15. Cha RM, Khatri M, and Sharma JM: Protection against avian metapneumovirus subtype C in turkeys immunized via the respiratory tract with inactivated virus. Vaccine 2011;29:459-465.
16. Cheng LE, Ohlen C, Nelson BH, and Greenberg PD: Enhanced signaling through the IL-2 receptor in CD8 + T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8 + T cells rather than promotion of cell death. Proc Natl Acad Sci USA 2002;99:3001-3006.
17. Chin AI, Miyahira AK, Covarrubias A, et al.: Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010;70:2595-2603.
18. Chowdhury D, and J Lieberman: Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 2008;26:389-420.
19. Djeraba A, Kut E, Rasschaert D, and Quere P: Antiviral and antitumoral effects of recombinant chicken myelomonocytic growth factor in virally induced lymphoma. Int Immunopharmacol 2002;2:1557-1566.
20. Dooms H, Kahn E, Knoechel B, and Abbas AK: IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol 2004;172:5973-5979.
21. Dooms H, Wolslegel K, Lin P, and Abbas AK: Interleukin-2 enhances CD4 + T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med 2007;204:547-557.
22. Endharti AT, Rifa'I M, Shi Z, et al.: Cutting edge: CD8+ CD122 + regulatory T cells produce IL-10 to suppress IFNgamma production and proliferation of CD8 + T cells. J Immunol 2005;175:7093-7097.
23. Gaajetaan GR, Geelen TH, Grauls GE, Bruggeman CA, and Stassen FR: CpG and poly(I:C) stimulation of dendritic cells and fibroblasts limits herpes simplex virus type 1 infection in an IFNb-dependent and-independent way. Antiviral Res 2012;93:39-47.
24. Gibbert K, Dietze KK, Zelinskyy G, et al.: Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 2010;185:6179-6189.
25. Guermonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-667.
26. Hansell C, Zhu XW, Brooks H, et al.: Unique features and distribution of the chicken CD83 + cell. J Immunol 2007;179: 5117-5125.
27. Haq K, Elawadli I, Parvizi P, Mallick AI, Behboudi S, and Sharif S: Interferon-gamma influences immunity elicited by vaccines against very virulent Marek's disease virus. Antiviral Res 2011;90:218-226.
28. Heidari M, Zhang HM, and Sharif S: Marek's disease virus induces Th-2 activity during cytolytic infection. Viral Immunol 2008;21:203-214.
29. Ichinohe T, Ainai A, Ami Y, et al.: Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010;82:1754-1761.
30. Ichinohe T, Kawaguchi A, Tamura S, et al.: Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007;9: 1333-1340.
31. Jenkins KA, Lowenthal JW, Kimpton W, and Bean AG: The in vitro and in ovo responses of chickens to TLR9 subfamily ligands. Dev Comp Immunol 2009;33:660-667.
32. Jiang J, Gross D, Nogusa S, Elbaum P, and Murasko DM: Depletion of T cells by type I interferon: differences between young and aged mice. J Immunol 2005;175:1820-1826.
33. Kaiser WJ, and Offermann MK: Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 2005;174:4942-4952.
34. Karpala AJ, Lowenthal JW, and Bean AG: Activation of the TLR3 pathway regulates IFNbeta production in chickens. Dev Comp Immunol 2008;32:435-444.
35. Kim CH, Park CD, and Lee AY: Administration of poly (I:C) improved dermatophagoides farinae-induced atopic dermatitis-like skin lesions in NC/Nga mice by the regulation of Th1/Th2 balance. Vaccine 2011;30:2405-2410.
36. Kovalcsik E, Lowe K, Fischer M, Dalgleish A, and Bodman-Smith MD: Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. Cancer Immunol Immunother 2011;60:1609-1624.
37. Liew FY: T(H)1 and T(H)2 cells: a historical perspective. Nat Rev Immunol 2002;2:55-60.
38. Mallick AI, Kulkarni RR, St Paul M, Parvizi P, Behboudi S, and Sharif S: Vaccination with CpG-adjuvanted avian influenza virosomes promotes anti-viral immune responses and reduces virus shedding in chickens. Accepted for publication in Viral Immunol.
39. Osterrieder N, Kamil JP, Schumacher D, Tischer BK, and Trapp S: Marek's disease virus: from miasma to model. Nat Rev Microbiol 2006;4:283-294.
40. Parvizi P, Read L, Abdul-Careem MF, Lusty C, and Sharif S: Cytokine gene expression in splenic CD4( + ) and CD8( +) Tcell subsets of chickens infected with Marek's disease virus. Viral Immunol 2009;22:31-38.
41. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
42. Rothwell L, Young JR, Zoorob R, et al.: Cloning and characterization of chicken IL-10 and its role in the immune response to Eimeria maxima. J Immunol 2004; 173:2675-2682.
43. Schat KA, and Baranowski E: Animal vaccination and the evolution of viral pathogens. Rev Sci Tech 2007;26:327-338.
44. Schroder M, and Bowie AG: TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005;26:462-468.
45. Shack LA, Buza JJ, and Burgess SC: The neoplastically transformed (CD30(hi)) Marek's disease lymphoma cell phenotype most closely resembles T-regulatory cells. Cancer Immunol Immunother 2008;57:1253-1262.
46. Tarpey I, Davis PJ, Sondermeijer P, et al.: Expression of chicken interleukin-2 by turkey herpesvirus increases the immune response against Marek's disease virus but fails to increase protection against virulent challenge. Avian Pathol 2007;36:69-74.
47. Witter RL: Epidemiological studies relating to the control of Marek's disease. Worlds Poult Sci J 1970;26:755-762.